Full Press Release Details
SAN FRANCISCO,Sept. 3, 2025/PRNewswire/ -- Nektar Therapeutics (Nasdaq:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27thAnnual Global Investment Conference being heldSeptember 8-10, 2025inNew York Cityand the Stifel Virtual Immunology and Inflammation Forum being heldSeptember 15-16, 2025.
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website:https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase2bclinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered inSan Francisco, California. For further information, visitwww.nektar.comand follow Nektar on LinkedIn.
For Investors:
Vivian Wu of Nektar Therapeutics628-895-0661